Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATI-2173 Safety and PK in Healthy and Chronic HBV Subjects
NCT04248426Phase 1Completed
- Sponsor
- Antios Therapeutics
- Start
- Feb 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing ATI-2173 with Placebo (2 arms). Primary endpoints: Treatment-Emergent Adverse Events at 1 year, Treatment-Emergent Serious Adverse Events at 1 year and 3 more. Started Feb 2020; status: completed.
02
Drugs
ATI-2173
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04248426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04248426.